Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amicus Therapeutics (FOLD)
NASDAQ:FOLD
Holding FOLD?
Track your performance easily
FOLD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.02 - $14.57
Previous Close$9.5
Volume808.76K
Average Volume (3M)2.37M
Market Cap
$2.88B
Enterprise Value$3.03B
Total Cash (Recent Filing)$249.76M
Total Debt (Recent Filing)$444.66M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Feb 26, 2025EPS Estimate
$0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding298,805,773
10 Day Avg. Volume2,692,991
30 Day Avg. Volume2,371,174
Standard Deviation0.15
R-Squared0.06
Alpha0.00732
Financial Highlights & Ratios
Price to Book (P/B)15.98
Price to Sales (P/S)5.76
Price to Cash Flow (P/CF)-31.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.14
Enterprise Value/Gross Profit8.38
Enterprise Value/Ebitda-349.21
Forecast
1Y Price Target
$17.89Price Target Upside85.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Amicus News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAmicus reported a third quarter beat for both products; Galafold revenue guidance is being raised for the third time this year.
Geographic ExpansionFOLD continues to expand to new countries, with Czech Republic recently approved on pricing and reimbursement along with Germany, UK, US, Austria, and Spain.
Revenue GrowthFY24 revenue growth guidance was raised/tightened to 30%-32% from 26%-31%, with maintained combined peak revenue potential guidance of $1.5B-2B.
Bears Say
Patent LitigationConsidering some Galafold patents expire in the late 2020s and the risk of a skinny label approval, the litigation remains a concern.
Patient GrowthPatient growth quarter over quarter has slowed modestly.
Stock ValuationAnalyst views FOLD shares as fully valued at current levels and maintains a Hold rating.
---
Ownership Overview
1.15% Insiders
33.27% Mutual Funds
38.56% Other Institutional Investors
10.32% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
FOLD FAQ
What was Amicus Therapeutics’s price range in the past 12 months?
Amicus Therapeutics lowest stock price was $9.02 and its highest was $14.57 in the past 12 months.
What is Amicus Therapeutics’s market cap?
Currently, no data Available
When is Amicus Therapeutics’s upcoming earnings report date?
Amicus Therapeutics’s upcoming earnings report date is Feb 26, 2025 which is in 95 days.
How were Amicus Therapeutics’s earnings last quarter?
Amicus Therapeutics released its earnings results on Nov 06, 2024. The company reported -$0.02 earnings per share for the quarter, missing the consensus estimate of $0.001 by -$0.021.
Is Amicus Therapeutics overvalued?
According to Wall Street analysts Amicus Therapeutics’s price is currently Undervalued.
Does Amicus Therapeutics pay dividends?
Amicus Therapeutics does not currently pay dividends.
What is Amicus Therapeutics’s EPS estimate?
Amicus Therapeutics’s EPS estimate is $0.02.
How many shares outstanding does Amicus Therapeutics have?
Amicus Therapeutics has 298,805,800 shares outstanding.
What happened to Amicus Therapeutics’s price movement after its last earnings report?
Amicus Therapeutics reported an EPS of -$0.02 in its last earnings report, missing expectations of $0.001. Following the earnings report the stock price went down -4.259%.
Which hedge fund is a major shareholder of Amicus Therapeutics?
Among the largest hedge funds holding Amicus Therapeutics’s share is Perceptive Advisors LLC. It holds Amicus Therapeutics’s shares valued at 300M.
---
Amicus Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.89 (85.29% Upside)
$17.89 (85.29% Upside)
Blogger Sentiment
Bullish
FOLD Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 996.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $351.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 26.5%
Last 30 Days ▲ 26.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.71%
12-Months-Change
Fundamentals
Return on Equity
-67.09%
Trailing 12-Months
Asset Growth
2.94%
Trailing 12-Months
Company Description
Amicus Therapeutics
Amicus Therapeutics, Inc. engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.
---
FOLD Company Deck
---
FOLD Earnings Call
Q3 2024
0:00 / 0:00
---
FOLD Stock 12 Month Forecast
Average Price Target
$17.89
▲(85.29% Upside)
Technical Analysis
Best Analysts Covering FOLD
1 Year
1 Year Success Rate
8/13 ratings generated profit
1 Year Average Return
+26.41%
reiterated a buy rating 16 days ago
Copying Debjit Chattopadhyay's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +26.41% per trade.
---